

Company Overview

CollPlant is a regenerative medicine company focused on 3D bioprinting of tissues and organs, and on developing and commercializing tissue repair products for orthobiologics, and advanced wound care markets. Our products are based on our rhCollagen (recombinant human collagen) that is produced with CollPlant's proprietary plant based genetic engineering technology.

Our products address indications for diverse fields of organ and tissue repair, and are ushering in a new era in regenerative medicine. Our flagship rhCollagen Biolnk product line is ideal for 3D bioprinting of tissues and organs, and our unique Vergenix line of rhCollagen products includes a soft tissue repair matrix for treating tendinopathy and a wound repair matrix to promote a rapid optimal healing of acute and chronic wounds.

CollPlant Launches New HQ and R&D Center in Israel

May 22 2019, 8:41 AM EDT

Stock Overview

Symbol	CLGN
Exchange	Nasdaq
Market Cap	15.75m
Last Price	\$4.13
52-Week	\$3.13 - \$8.73

05/24/2019 03:56 PM EDT

Investor Relations

Eran Rotem
Deputy CEO & CFO
T: +972 (73) 2325612
F: +972 (73) 2325602
eran@collplant.com

Corporate Profile@
Laurel Moody
1185 Avenue of the Americas 3rd Floor
New York, NY 10036
T: +1 212 931 8787 Ext 101

Cybele Holdings Ltd.
Yael Schnitzer
T: +972(3)5755123
yael@cybele.co.il

Management Team

Yehiel Tal
Chief Executive Officer

Prof. Oded Shoseyov
Founder, Chief Scientific Officer

Eran Rotem, CPA
Deputy CEO and Chief Financial Officer

Dr. Nadav Orr
Vice President, Research and Development

Dr. Ilana Belzer
Chief Operating Officer

Dr. Philippe Bensimon
Vice President, Regulatory Affairs and Quality Assurance

CollPlant Holdings Ltd.

4 Oppenheimer St.,
P.O.B 4132
Rehovot 7670104,
Israel

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.